Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
Science Translational Medicine, 2020
Raeber M., Rosalia R., Schmid D., Karakus U., Boyman O.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology Immunotherapy | Pathophysiology | Serum |  Olink Target 96 |
Abstract
IL-2 immunotherapy expands tumor-infiltrating DCs through a lymphoid pathway, favoring the conversion of poorly immunogenic into immunogenic tumors.